Breast Cancer Treatment Based on Organ-like Culture
NCT03925233 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2019-04-24
Summary
Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses the possible mechanism of breast cancer drug resistance.
Conditions
- Breast Cancer Organoids
Interventions
- DRUG
-
Trastuzumab Injection
- DRUG
-
Doxorubicin Hydrochloride
Doxorubicin Hydrochloride Injection
- DRUG
-
Epirubicin hydrochloride
Epirubicin hydrochloride injection
- DRUG
-
Fluorouracil injection
- DRUG
-
Paclitaxel injection
- DRUG
-
Gemcitabine injection
- DRUG
-
Cisplatin injection
- DRUG
-
Recombinant Human Endostatin
Recombinant Human Endostatin Injection
- DRUG
-
Pirarubicin hydrochloride
Pirarubicin hydrochloride injection
- DRUG
-
Pyrrolidine
Pyrrolidine tablets
- DRUG
-
Ixabepilone
Ixapilone Injection
- DRUG
-
Tamoxifen citrate
Tamoxifen citrate tablets
- DRUG
-
Vinorelbine tartrate
Vinorelbine tartrate injection
- DRUG
-
Carboplatin injection
- DRUG
-
Methotrexate
Methotrexate injection
- DRUG
-
Eribulin mesylate
Eribulin mesylate injection
- DRUG
-
Toremifene citrate
Toremifene citrate tablets
- DRUG
-
Anastrozole
Anastrozole tablets
- DRUG
-
Letrozole tablets
- DRUG
-
Exemestane
Exemestane tablets
- DRUG
-
Fulvestrant injection
- DRUG
-
Olapani pill
- DRUG
-
Bevacizumab injection
- DRUG
-
Apatinib mesylate
Apatinib mesylate tablets
- DRUG
-
Pattozumab
Pattozumab injection
- DRUG
-
Capecitabine tablets
- DRUG
-
Ear particles
Ear particles
- DRUG
-
Aidi Injection
Aidi Injection
- DRUG
-
Cyclophosphamide injection
Sponsors & Collaborators
-
Xijing Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-01-02
- Primary Completion
- 2021-12-15
- Completion
- 2021-12-15
- FDA Drug
- Yes
Countries
- China
Study Locations
More Related Trials
-
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
NCT03933319 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NCT07095023 ·Status: RECRUITING ·Phase: NA
-
Study the Role of Stem Cell in Curing Drug Induced Liver Injury in Metastatic Breast Cancer (MBC)
NCT01231022 ·Status: COMPLETED
-
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
NCT00003927 ·Status: COMPLETED ·Phase: PHASE1
-
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
NCT02003209 ·Status: COMPLETED ·Phase: PHASE3
-
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
NCT00499083 ·Status: COMPLETED ·Phase: PHASE2
-
Pegylated Liposomal Doxorubicin Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer
NCT03994107 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
NCT00353483 ·Status: RECRUITING
-
R101933 Combined With Chemotherapy in Treating Patients With Metastatic Breast Cancer That Has Not Responded to Previous Chemotherapy
NCT00028873 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating Xihuang Pill to Improve the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
NCT05914753 ·Status: UNKNOWN ·Phase: NA
-
A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer
NCT05257395 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT07043725 ·Status: RECRUITING ·Phase: PHASE3
-
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
NCT05953168 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
NCT00436566 ·Status: COMPLETED ·Phase: PHASE2
-
Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer
NCT03373708 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
NCT04290793 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
AKT Inhibitor in Oestrogen Positive Breast Cancer
NCT02077569 ·Status: COMPLETED ·Phase: PHASE2
-
AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer
NCT00310089 ·Status: COMPLETED ·Phase: NA
-
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
NCT06344793 ·Status: COMPLETED
-
Combination Chemotherapy in Treating Women With Stage IIIB or Stage IV Breast Cancer
NCT00003352 ·Status: COMPLETED ·Phase: PHASE2
-
CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
NCT04059003 ·Status: UNKNOWN
-
NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer
NCT02689921 ·Status: UNKNOWN ·Phase: PHASE2
-
Drug Sensitivity of Hydrothorax and Ascite Organoids from Breast Cancer
NCT06658080 ·Status: RECRUITING
-
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
NCT07093931 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4